Sermorelin: the GHRH fragment that used to be an approved drug

The first twenty-nine amino acids of growth hormone releasing hormone, which is the whole active part of the hormone. It has an unusual regulatory history for a compound in this category: it used to be an approved medicine.

The active fragment, unmodified

Established clinical use Native GHRH is 44 amino acids long and its biological activity resides in the first 29. Sermorelin is exactly that fragment, synthesised without modification. It binds the GHRH receptor on pituitary somatotrophs and stimulates growth hormone release, working entirely within the axis's own feedback: somatostatin still suppresses release between pulses, and the pituitary's own regulation stays in place.

Because it is unmodified, it is degraded quickly. The app models a half-life of about twelve minutes, which is the shortest of any compound in this reference and is a property of the native sequence rather than a formulation problem. Modified GRF(1-29) — the peptide usually sold as CJC-1295 without DAC — is this molecule with four substitutions that resist that degradation, which is why its half-life is measured in tens of minutes instead.

A twelve-minute half-life produces a sharp, brief stimulus. That is closer to what the hypothalamus actually does than any longer-acting analogue manages, and it is the basis for describing sermorelin as the most physiological intervention in this class. It also means the effect depends heavily on a pituitary able to respond, which is why the historical clinical use was diagnostic as much as therapeutic.

An approval that no longer exists

Established clinical use Sermorelin was marketed in the United States as an approved product for growth hormone deficiency in children, used both to assess pituitary function and to treat. It was withdrawn from the market in the late 2000s. The withdrawal was a commercial decision rather than a safety action, and that distinction matters when reading its current status: this is not a compound that failed, it is one that stopped being sold.

What it is now is a compounded preparation without an approved product behind it, which the app records as research-compound status. The practical consequence is the same as for any unapproved compound: identity, purity and concentration depend on the preparer, and no regulator has reviewed them. This site names no pharmacy, vendor or testing service.

That history is also why the safety picture is better characterised than for most peptides in this reference. A drug that was approved and used clinically for years has an adverse-effect profile derived from clinical use rather than from animal work, and sermorelin's is unremarkable: injection-site reactions, occasional flushing, and the effects of raising growth hormone at higher exposures.

What to expect and what to measure

Off-label or community practice Use in adults for body composition, sleep or recovery is off-label and rests on the same gap that affects the whole class: raising GH pulses in a person with a normal axis is a measurable intervention with an unmeasured benefit. Sermorelin is less potent than the modified analogues and than the GHRH-plus-secretagogue pairings, which is the trade-off for being closest to the native signal.

IGF-1 is the marker that tells you whether the axis moved, for the same reason it is on every page in this class: a random serum growth hormone reports where in a pulse the draw happened and little else. The IGF-1 page covers the age-dependent range. Fasting glucose sits beside it because raising growth hormone reduces insulin sensitivity.

Administration is described fasted and before sleep because insulin blunts GH release and the largest natural pulse is nocturnal — the same constraints that apply to every compound in this class. Anything experienced while using it belongs with a clinician who has the full history rather than being managed against a page.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Sermorelin half-life and steady state.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Sermorelin, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• IGF-1
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app's own entry, and notably mild — which is what you would expect from a molecule identical to a fragment of a native hormone, cleared in minutes.

• Less potent than CJC-1295 + Ipamorelin
• Requires daily dosing
• Short half-life
• Results slower than HGH
• Requires refrigeration and reconstitution

Questions people actually ask

How is sermorelin different from CJC-1295 without DAC?

They are the same 29-residue sequence, except that modified GRF(1-29) carries four amino acid substitutions that resist enzymatic degradation. That raises the half-life from about twelve minutes to about thirty. Everything else — receptor, mechanism, feedback — is the same. The CJC-1295 page covers the naming problem in that family.

Is it safer than growth hormone itself?

It works through the pituitary rather than replacing its output, so the axis's own feedback limits how far growth hormone can rise — which is a genuine structural difference from injecting somatropin. That is an argument about mechanism, not a safety finding, and it does not make an unapproved compounded preparation equivalent to a regulated product.

Why did it stop being available as an approved drug?

The withdrawal was commercial rather than a safety action. That distinction is worth carrying, because "withdrawn from the market" reads as a safety event and in this case was not one.

How short is twelve minutes in practice?

Short enough that the peptide is effectively gone within an hour. The growth hormone pulse it triggers and the IGF-1 response that follows last far longer, which is why the half-life does not describe the duration of effect. The half-life page has the curve.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.